Amazon introduces AI powered platform for faster drug development

What is Amazon Bio Discovery?

Amazon just launched Amazon Bio Discovery, a new AI tool that helps scientists find new medicines faster. It comes from Amazon Web Services (AWS), the company’s cloud computing arm.

The tool is built for early-stage drug discovery, especially for antibody treatments. Researchers can use it without writing any code, which makes complex science much more accessible.

How Amazon Bio Discovery works

Amazon Bio Discovery gives researchers access to over 40 special AI models. These models are trained on huge amounts of biological data and can generate and test virtual drug molecules.

Scientists can talk to an AI agent using plain English. This helper picks the right models, runs experiments, and even explains its reasoning. No coding skills are required.

From months to just weeks

One cancer center used Amazon Bio Discovery to design nearly 300,000 new antibody molecules. They sent the top 100,000 candidates to a lab for testing.

What normally takes up to a full year got done in only a few weeks. That is a huge time saver when patients are waiting for new treatments to be developed.

No coding skills needed

In the past, using AI for drug research often required coding skills and access to specialized computing infrastructure. Amazon Bio Discovery is designed to reduce that barrier by giving scientists a no-code way to run early-stage antibody discovery workflows.

Now, bench scientists can run complex experiments without writing a single line of code. The tool handles the heavy computing so researchers can focus on biology instead.

Fun fact: Over 90% of drug candidates fail during preclinical testing, with the main reasons being lack of effectiveness or toxicity problems.

Closing the lab loop

Once the AI picks promising drug candidates, you can send them directly to real labs. Partners like Twist Bioscience and Ginkgo Bioworks will physically make and test the molecules.

The lab results automatically come back into the software. This creates a continuous loop where each round of testing makes the next one smarter and more accurate.

Your data stays yours

Some folks worry about sharing secret research with a big tech company. Amazon says all your data and discoveries stay completely private and secure.

You own everything you create with Amazon Bio Discovery. The platform is built with strong security that big pharmaceutical companies already trust for their most sensitive work.

Fine-tune with your own data

Scientists can feed their own past lab results into the AI models. With just a few clicks, the tool learns from that private data and makes better predictions.

You don’t need a special machine learning team to make this work. The fine-tuned models stay inside your organization and never get shared with anyone else.

Fun fact: AWS and the Gray Lab at Johns Hopkins Engineering unveiled the Antibody Developability Benchmark for AI-guided antibody design, the largest public collection of therapeutic antibody data available.

A library of AI models

Amazon Bio Discovery comes with a big catalog of ready-to-use AI models. Some are open source, and others come from partners like Apheris and Boltz.

There is also a benchmark dataset to compare which model works best. Think of it like trying on different shoes to see which fits your specific research project.

Who is already using it?

Big names like Bayer, the Broad Institute, and Voyager Therapeutics are early users of Amazon Bio Discovery. Memorial Sloan Kettering Cancer Center helped test the platform.

Even more impressive, 19 out of the top 20 drug companies worldwide already use AWS for other research. So this is not some untested experiment.

Not replacing scientists

You might worry that AI will take away lab jobs. But Amazon says this tool is meant to help scientists, not replace them at all.

An expert at AWS explained that the goal is to augment researchers. The AI handles repetitive tasks so people can focus on creative problem-solving and making real discoveries.

Big pharma trusts AWS

A Jefferies analyst said fears about AI reducing the need for lab instruments are overblown. In fact, better AI could lead to more investment in research tools.

As drug programs speed up and improve, companies may spend even more on equipment. That means good news for both patients and the entire science industry.

The wet lab connection

Amazon Bio Discovery combines computer design with wet-lab validation in one system. This means scientists can go from virtual testing to physical testing without manual handoffs.

The continuous back-and-forth between AI and real labs allows for rapid fine-tuning. Each experiment makes the next one better and faster.

Want to see how AI is already shaking things up inside Amazon itself? Take a look at how its own tools are disrupting operations; it’s a revealing read.

What is next for AI drugs?

Right now, Amazon Bio Discovery is focused on early-stage antibody discovery. AWS positions it as a platform for designing and evaluating potential antibody therapies with AI-guided workflows.

More benchmark datasets will be added over time to help researchers compare models more effectively. Those benchmarks are intended to support model selection and evaluation within the platform.

Curious how Amazon’s broader moves are landing with people inside the company? Take a look at the reaction to its Super Bowl ad.

If you found this slideshow helpful or interesting, drop a like and share your thoughts in the comments. What would you want AI to cure first?

This slideshow was made with AI assistance and human editing.

Don’t forget to follow us for more exclusive content on MSN.

Read More From This Brand:

• 18 Robotics Innovations Changing The Workplace
• Amazon Sellers Stock Up as New Tariffs Skyrocket Prices
• Amazon starts using humanoid robots for faster shipments